Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | TET3 | O43151 | 2/20 | 0.43 |
| ▸ | FBXL19 | Q6PCT2 | 2/20 | 0.43 |
| ▸ | CXXC5 | Q7LFL8 | 2/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.43 |
| ▸ | CXXC4 | Q9H2H0 | 2/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.43 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31158334 | 0.89 | TSHR (0.48) | TSHRALOX15ATMKMT2AMEN1 | |
| SCHEMBL10447211 | 0.89 | TSHR (0.48) | TSHRALOX15ATMKMT2AMEN1 | |
| SCHEMBL31382358 | 0.88 | TSHR (0.50) | TSHRALOX15ATMKMT2AMEN1 | |
| SCHEMBL972474 | 0.86 | TSHR (0.65) | TSHRALOX15ATMKMT2ACCR5 | |
| SCHEMBL28029029 | 0.86 | TSHR (0.52) | TSHRALOX15ATMKMT2AMEN1 | |
| SCHEMBL31694033 | 0.86 | TSHR (0.52) | TSHRALOX15ATMKMT2AMEN1 | |
| SCHEMBL704139 | 0.85 | OPRM1 (0.50) | TSHRALOX15ATMCCR5OPRD1 | |
| SCHEMBL3028439 | 0.85 | STS (0.50) | TSHRALOX15ATMKMT2AMEN1 | |
| SCHEMBL29892887 | 0.85 | STS (0.50) | TSHRALOX15ATMKMT2AMEN1 | |
| SCHEMBL654813 | 0.85 | KMT2A (0.59) | TSHRALOX15ATMKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303040-B2 | Substituted piperazines as AKT inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-04-05 | — | — | US | disclosed |
| CN-101516891-B | Dihydrothieno pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC | 2013-06-05 | — | — | CN | disclosed |
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2054418-B1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2011-11-09 | — | — | EP | disclosed |
| CN-101516891-A | Dihydrothieno pyrimidines as AKT protein kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2009-08-26 | — | — | CN | disclosed |
| EP-2054418-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008006039-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329808-A1 | DIHYDROTHIENO PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | DTYMK, TK1, PIK3CA | TSHR 3756/4885ALOX15 3962/4885ATM 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.